[This entry is marked for removal.]

Bayer HealthCare Pharmaceuticals Inc. (formerly Berlex Laboratories Inc) is the U.S.-based pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG.
Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals is comprised of the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology and Oncology.

See also Bayer Schering Pharma AG.

Berlex Laboratories has been integrated into Bayer HealthCare, and operates as an integrated specialty pharmaceuticals business under a new name, Bayer HealthCare Pharmaceuticals.
The company is developing and making specialized medicines for treating multiple sclerosis, dermatological disorders, female health concerns, cancer and is creating new diagnostic imaging techniques. Berlex Laboratories, Inc. was a pioneer in the imaging market. It introduced a broad range of imaging agents. Its contribution began in 1988 with the introduction of the world's first magnetic resonance imaging agent, Magnevist® (gadopentetate dimeglumine) injection. Berlex Laboratories, Inc. was an US affiliate of Bayer Schering Pharma AG Germany.

Imagent® is an injectable suspension for intravenous administration during a sonogram. This diagnostic contrast agent for enhancement of ultrasound images contains perflexane lipid microspheres. Imagent® US is indicated in the assessment of heart function and perfusion, as well as the detection of tumors and blood flow abnormalities by using gray scale, color Doppler, and harmonic ultrasound imaging techniques.
During the course of its development, the brand name for this product has changed from Imagent to Imavist (between August 2000 and March 2002) back to Imagent. The manufacturer's 06/03/02 press release announcing FDA approval refers to the product as 'Imagent (formerly Imavist),' and the approval notice and monograph posted at the FDA site refers to the product as Imagent.
Jointly developed by Alliance Pharmaceutical Corp and Bayer Schering Pharma AG (Germany). Source: PR Newswire - 10/10/96, 03/31/98, 10/13/99, 03/13/01, 10/08/01; FDA approvals - 05/31/02; Alliance Pharmaceutical press release - 06/03/02.
Currently the production of Imagent® is discontinued.